Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of 2-substituted 1 H -benzo[ d ]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity
Jie Zhou, Ming Ji, Zhixiang Zhu, et al.
European Journal of Medicinal Chemistry (2017) Vol. 132, pp. 26-41
Closed Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update
Priyancy G. Jain, Bhumika Patel
European Journal of Medicinal Chemistry (2019) Vol. 165, pp. 198-215
Closed Access | Times Cited: 116
Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer
Tingting Liu, Shubin Song, Xu Wang, et al.
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112954-112954
Closed Access | Times Cited: 59
Design of Selective PARP-1 Inhibitors and Antitumor Studies
Yiting Zhang, Xiangqian Li, Fang Liu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8877-8901
Closed Access | Times Cited: 7
New series of 4(3H)-quinazolinone derivatives: syntheses and evaluation of antitumor and antiviral activities
Samir Y. Abbas, Khairy A. M. El‐Bayouki, Wahid M. Basyouni, et al.
Medicinal Chemistry Research (2017) Vol. 27, Iss. 2, pp. 571-582
Closed Access | Times Cited: 59
Recent progress of research on anti‐tumor agents using benzimidazole as the structure unit
Kaiyue Wu, Xiaoyu Peng, Miaojia Chen, et al.
Chemical Biology & Drug Design (2022) Vol. 99, Iss. 5, pp. 736-757
Closed Access | Times Cited: 25
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
Xiaopeng Peng, Wanyi Pan, Feng Jiang, et al.
Pharmacological Research (2022) Vol. 186, pp. 106529-106529
Closed Access | Times Cited: 24
Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity
Jie Zhou, Ming Ji, Haiping Yao, et al.
Organic & Biomolecular Chemistry (2018) Vol. 16, Iss. 17, pp. 3189-3202
Closed Access | Times Cited: 43
Identification of 3-(benzazol-2-yl)quinoxaline derivatives as potent anticancer compounds: Privileged structure-based design, synthesis, and bioactive evaluation in vitro and in vivo
Qingqing Liu, Ke Lu, Hai-Miao Zhu, et al.
European Journal of Medicinal Chemistry (2019) Vol. 165, pp. 293-308
Closed Access | Times Cited: 39
Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2
Yu Jiang, Lingling Luo, Tong Hu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113898-113898
Closed Access | Times Cited: 30
Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment
Jie Zhang, Yuqi Gao, Zipeng Zhang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16099-16127
Closed Access | Times Cited: 22
Discovery of 5,6-diaryl-1,2,4-triazines hybrids as potential apoptosis inducers
Dong‐Jun Fu, Jian Song, Yuhui Hou, et al.
European Journal of Medicinal Chemistry (2017) Vol. 138, pp. 1076-1088
Open Access | Times Cited: 38
Design, synthesis and biological evaluation of homoerythrina alkaloid derivatives bearing a triazole moiety as PARP-1 inhibitors and as potential antitumor drugs
Shuai Li, Xinyang Li, Tingjian Zhang, et al.
Bioorganic Chemistry (2019) Vol. 94, pp. 103385-103385
Closed Access | Times Cited: 32
Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors
Shuai Li, Xinyang Li, Tingjian Zhang, et al.
Bioorganic Chemistry (2020) Vol. 96, pp. 103575-103575
Closed Access | Times Cited: 28
Development of 6-Methanesulfonyl-8-nitrobenzothiazinone Based Antitubercular Agents
Rui Shi, Bin Wang, Giovanni Stelitano, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 4, pp. 593-598
Open Access | Times Cited: 15
Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer
Lan Zhang, Yongqi Zhen, Feng Lu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115648-115648
Closed Access | Times Cited: 9
Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing 3-Substituted Piperizines as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis
Jie Zhou, Ming Ji, Xiaoyu Wang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 22, pp. 16711-16730
Closed Access | Times Cited: 18
Synthesis of New Bioactive Indolyl-1,2,4-Triazole Hybrids As Dual Inhibitors for EGFR/PARP-1 Targeting Breast and Liver Cancer Cells
Mohamed F. Youssef, Mohamed S. Nafie, Eid E. Salama, et al.
ACS Omega (2022) Vol. 7, Iss. 49, pp. 45665-45677
Open Access | Times Cited: 13
Current progress in the targeted therapy of breast cancer: Structure–activity correlation and docking studies (2015–2021)
Shivanshu Pandey, Sitanshu Mondal, Kumari Kajal, et al.
Archiv der Pharmazie (2023) Vol. 356, Iss. 8
Closed Access | Times Cited: 7
Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship
Amandeep Thakur, Mandeep Rana, Ritika Ritika, et al.
Bioorganic Chemistry (2023) Vol. 141, pp. 106893-106893
Closed Access | Times Cited: 7
Identification of organic pollutants and heavy metals in natural rubber wastewater and evaluation its phytotoxicity and cytogenotoxicity
Dayu Zhu, Chengjun Ge, Ying Sun, et al.
Chemosphere (2023) Vol. 349, pp. 140503-140503
Closed Access | Times Cited: 7
Benzoxaboroles—Novel Autotaxin Inhibitors
Kristina Kraljić, Dubravko Jelić, Dinko Žiher, et al.
Molecules (2019) Vol. 24, Iss. 19, pp. 3419-3419
Open Access | Times Cited: 21
Recent advances in structural types and medicinal chemistry of PARP-1 inhibitors
Ling Yu, Zhiwei Yan, Youde Wang, et al.
Medicinal Chemistry Research (2022) Vol. 31, Iss. 8, pp. 1265-1276
Closed Access | Times Cited: 12
Targeting selective inhibitors of PARPs in drug discovery and development
Maolin Duan, Jing Gao, Jiajin Li, et al.
Medicinal Chemistry Research (2024) Vol. 33, Iss. 10, pp. 1734-1756
Closed Access | Times Cited: 2
Design and synthesis of some barbituric and 1,3-dimethylbarbituric acid derivatives: A non-classical scaffold for potential PARP1 inhibitors
Essam Eldin A. Osman, Noura S. Hanafy, Riham F. George, et al.
Bioorganic Chemistry (2020) Vol. 104, pp. 104198-104198
Closed Access | Times Cited: 18
One-pot synthesis, physicochemical and photophysical properties of deep blue light-emitting highly fluorescent pyrene-imidazole dye: A combined experimental and theoretical study
Salman A. Khan, Abdullah M. Asiri, Al-Anood M. Al-Dies, et al.
Journal of Photochemistry and Photobiology A Chemistry (2018) Vol. 364, pp. 390-399
Closed Access | Times Cited: 13
Page 1 - Next Page

Scroll to top